Known targets — ChEMBL curated mechanism
PRKAA1PRKAA2PRKAB1PRKAB2PRKAG1PRKAG2PRKAG3
The experimentally established mechanism targets of Acadesine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.91 |
| ▸ | TP53 | P04637 | 2/20 | 0.91 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.91 |
| ▸ | MAPT | P10636 | 1/20 | 0.91 |
| ▸ | ATIC | P31939 | 2/20 | 0.74 |
| ▸ | FBP1 | P09467 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | HTT | P42858 | 2/20 | 0.70 |
| ▸ | BLM | P54132 | 2/20 | 0.70 |
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | THPO | P40225 | 2/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.55 |
| ▸ | GMNN | O75496 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.55 |
| ▸ | MTOR | P42345 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acadesine SCHEMBL30433377 | 1.00 | KDM4E (0.91) | KDM4ETP53TDP1MAPTATIC | |
| Acadesine SCHEMBL5053863 | 0.95 | KDM4E (1.00) | KDM4ETP53TDP1MAPTATIC | |
| Acadesine SCHEMBL10017743 | 0.95 | KDM4E (1.00) | KDM4ETP53TDP1MAPTATIC | |
| Acadesine SCHEMBL14520658 | 0.95 | KDM4E (1.00) | KDM4ETP53TDP1MAPTATIC | |
| Acadesine SCHEMBL7141001 | 0.95 | KDM4E (1.00) | KDM4ETP53TDP1MAPTATIC | |
| Acadesine SCHEMBL6113798 | 0.95 | KDM4E (1.00) | KDM4ETP53TDP1MAPTATIC | |
| Acadesine SCHEMBL2631614 | 0.95 | KDM4E (1.00) | KDM4ETP53TDP1MAPTATIC | |
| Acadesine SCHEMBL2394079 | 0.95 | KDM4E (1.00) | KDM4ETP53TDP1MAPTATIC | |
| Acadesine SCHEMBL28745421 | 0.95 | KDM4E (1.00) | KDM4ETP53TDP1MAPTATIC | |
| Acadesine SCHEMBL2619704 | 0.95 | KDM4E (1.00) | KDM4ETP53TDP1MAPTATIC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834469-B2 | AMP-activated protein kinase activating compounds and uses thereof | SKYLARK BIOSCIENCE LLC (US) | 2023-12-05 | — | — | US | disclosed |
| US-11779590-B2 | AMP-activated protein kinase activating compounds and uses thereof | SKYLARK BIOSCIENCE LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-20220133765-A1 | AMP-ACTIVATED PROTEIN KINASE ACTIVATING COMPOUNDS AND USES THEREOF | SKYLARK BIOSCIENCE LLC (US) | 2022-05-05 | — | — | US | disclosed |
| US-20210230209-A1 | AMP-ACTIVATED PROTEIN KINASE ACTIVATING COMPOUNDS AND USES THEREOF | SKYLARK BIOSCIENCE LLC (US) | 2021-07-29 | — | — | US | disclosed |
| EP-3833359-A2 | AMP-ACTIVATED PROTEIN KINASE ACTIVATING COMPOUNDS AND USES THEREOF | Skylark Bioscience LLC (US) | 2021-06-16 | — | — | EP | disclosed |
| CN-112739352-A | Compounds that activate AMP-activated protein kinase and uses thereof | 斯凯拉克生物科技有限责任公司 | 2021-04-30 | — | — | CN | disclosed |
| US-5827831-A | Lipid nucleotide analog prodrugs for oral administration | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-10-27 | — | — | US | disclosed |
| US-5744592-A | IMPROVING THE BIOAVAILABILITY AND ABSORPTION OF A DRUG THROUGH THE DIGESTIVE TRACT BY COVALENTLY BONDING THE DRUG AND A 1-O-OR-S-ALKYL-SN-GLYCERO-3-PHOSPHATE | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-04-28 | — | — | US | disclosed |
| US-5506347-A | ADENOSINE KINASE INHIBITOR | GENSIA, INC. (US) | 1996-04-09 | — | — | US | disclosed |
| US-5484809-A | ANTITUMOR | VESTAR, INC. (US) | 1996-01-16 | — | — | US | disclosed |
| US-5411947-A | converting drugs having suitable functional groups to 1-O-alkyl-, 1-O-acyl-, 1-S-acyl, and 1-S-alkyl-sn-glycero-3-phosphate derivatives; drugs such as AZT, cladribine, AICA-Riboside | VESTAR, INC. (US) | 1995-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230209-A1 | AMP-ACTIVATED PROTEIN KINASE ACTIVATING COMPOUNDS AND USES THEREOF | PRKAG1, PRKAG2, PRKAG3 | KDM4E 3446/4885TP53 858/4885TDP1 1958/4885 |
| US-20220133765-A1 | AMP-ACTIVATED PROTEIN KINASE ACTIVATING COMPOUNDS AND USES THEREOF | MYLK2, PRKAG1, PRKAG3 | KDM4E 2380/4885TP53 432/4885TDP1 221/4885 |
| US-11779590-B2 | AMP-activated protein kinase activating compounds and uses thereof | MYLK2, PRKAG1, PRKAG3 | KDM4E 2380/4885TP53 432/4885TDP1 221/4885 |
| US-11834469-B2 | AMP-activated protein kinase activating compounds and uses thereof | PRKAG1, PRKAG2, PRKAG3 | KDM4E 3603/4885TP53 898/4885TDP1 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.